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DISCLAIMER
The analyses upon which this publication is based were per-
formed under Contract HHSM-500-2006-RI, ‘‘Utilization
and Quality Control Peer Review Organization for the State
of Rhode Island,’’ sponsored by CMS, Department of Health
and Human Services. The contents of this publication do not
necessarily reflect the views or policies of the Department of
Health and Human Services, nor does mention of trade names,
commercial products, or organizations imply endorsement by
the U.S. government. The authors assume full responsibility for
the accuracy and completeness of the ideas presented. This ar-
ticle is a direct result of the Health Care Quality Improvement
Program initiated by CMS, which has encouraged identifica-
tion of quality improvement projects derived from analysis of
patterns of care and therefore required no special funding on
the part of this contractor. Feedback to the authors concerning
the issues presented is welcomed.
WITH THE INTRODUCTION OF MEDICARE PART D IN 2006, MEDICARE
Quality Improvement Organizations (QIOs) were directed
to collaborate with Medicare Part D prescription drug plan
providers to improve the safety, efficiency and effectiveness of
prescription drug use.1   Quality Partners of Rhode Island, the
Medicare-contracted QIO for Rhode Island, initiated an ef-
fort to improve the quality of medication use among that state’s
Medicare beneficiaries with diabetes mellitus. Selecting diabe-
tes presented a logical starting point, because epidemiologic
studies have described the under-use of medications.2-7 Addi-
tionally, patients with diabetes can be identified from phar-
macy claims data with an acceptable level of specificity.
This initiative sought to increase the use of lipid-lowering
and angiotensin-directed drug therapies (i.e. angiotensin-con-
verting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs)), from the perspective of both prescribing and
patient adherence. When this study was initiated, the Ameri-
can Diabetes Association (ADA) recommended that all senior
patients with diabetes be treated with statin therapy to achieve
cholesterol reduction, regardless of baseline LDL level.8 The
ADA also recommended that ACEI/ARB therapy be pre-
scribed for patients having both diabetes and hypertension, a
group which comprised “the majority of people with diabe-
tes”.8 The ADA noted that “ACE inhibitors have been shown
to improve cardiovascular outcomes in high–cardiovascular risk
patients with or without hypertension.”
Quality Partners collaborated with the University of Rhode
Island College of Pharmacy, provider groups, and several Medi-
care Part D drug plans in the state. The initiative included aca-
demic detailing by a clinical pharmacist, presentations at phy-
sician group meetings, dissemination of educational materials,
and targeted letters presenting physician-level prescribing rates
for ACEI/ARB and lipid-lowering therapies. The audience
learned  the utilization rates of ACEI/ARB and lipid-lowering
therapies among Part D plan enrollees having diabetes, and
the significant differences in the rates of use of these therapies
among sub-groups. This report presents that data.
METHODS
We conducted cross-sectional analyses of dispensings of
ACEI/ARB and lipid-lowering drugs for two 6-month peri-
ods: January 1 - June 30th, 2006; and January 1 - June 30th,
2007.   Pharmacy data were provided by several but not all
Medicare Part D prescription drug plans operating in Rhode
Island during 2006 and 2007. The pharmacy data included
patient age and gender; a prescriber identifier (DEA number);
the drug name and quantity, and the date of dispensing.  For
2007, information describing gender was missing for approxi-
mately one-third of patients and was imputed based on the
percentage of patients in the population for which gender was
documented.
Among patients receiving medications for diabetes, we
determined the percentage of patients who were dispensed an
ACEI/ARB and a lipid-lowering drug therapy at least once
during a 6-month period.  Lipid-lowering therapies included
both statin and non-statin medications.
We classified age as 50-64 years, 65-74 years, or 75 years of
age or older. We hypothesized that medication utilization would
be higher among patients with coronary artery disease, and we
used the proxy of receiving a prescription for a nitrate-contain-
ing product to identify this comorbidity. We also sought to de-
termine if ACEI/ARB and lipid-lowering therapy utilization rates
were higher among patients receiving care from one of the phy-
sician group practices that were participating in this initiative,
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and thus compared rates of use among patients receiving pre-
scriptions from physicians affiliated with these groups versus pa-
tients receiving prescriptions from physicians not affiliated with
these groups. ACEI/ARB and lipid-lowering therapy rates were
assessed among patients receiving at least one dispensing for any
medication from an endocrinologist as compared to patients who
did not receive prescriptions from an endocrinologist.
Within-group comparisons for each year were conducted,
and reported here as the frequency and percent of use of ACEI/
ARB and lipid-lowering medications. For these analyses we as-
sessed the statistical significance of group differences using the
chi-square test.
RESULTS
Part D pharmacy data were provided for nearly 38,000
Medicare beneficiaries, representing approximately 40% of the
population of beneficiaries enrolled in Medicare drug plans in
Rhode Island during 2006 and 2007. For 2006, we identified
5,009 patients who received medications for diabetes; in 2007,
7,331 such patients.
Table 1 presents descriptive statistics for the patients.  Most
were older: roughly 12% were younger than 65 years. Ap-
proximately 9% of patients received dispensings for nitrate-
containing medications. Slightly more than half of patients
(56%) received medications from a practitioner affiliated with
one of the collaborating group practices. Roughly 15% of pa-
tients received medication from an endocrinologist.
Table 2 presents overall rates of use of ACEI/ ARB and
lipid-lowering therapies for the two periods. For the analysis
using 2006 data, 69% of beneficiaries received at least one
dispensing for an ACEI or ARB medication, and 63% of pa-
tients received at least one dispensing for a lipid-lowering drug.
In the following year, 70% of patients received at least one
dispensing for an ACEI or ARB medication, and 65% received
at least one dispensing for a lipid-lowering drug. The increased
utilization of lipid-lowering therapy observed between 2006
and 2007 was statistically significant (p<0.05).
Table 3 presents the patient characteristics identified in
Table 1 by ACEI/ARB and lipid-lowering therapy utilization
for the 2007 period. Statistically significant differences (p<0.05)
were found for nearly all comparisons. Both the youngest and
oldest patient groups were found to be less likely to receive
these drug therapies, compared with patients in the 65-74 age
category. Women received these drug therapies more frequently
than men (74% versus 70% for ACEI/ARB therapy; 70% ver-
sus 63% for lipid therapies), as did patients who also received
dispensings for nitrate-containing products (75% versus 69%
for ACEI/ARB therapy; 77% versus 64% for lipid therapies).
Patients receiving prescriptions from physicians affiliated with
one of the group practice collaborators more frequently re-
ceived an ACEI/ARB or lipid-lowering therapy (72% versus
68% for ACEI/ARB therapy; 68% versus 62% for lipid-low-
ering therapies, p<0.05 for both comparisons ). Patients who
received prescription dispensings from an endocrinologist re-
ceived both ACEI/ARB and lipid-lowering therapies more fre-
quently, yet only the latter was a statistically significant differ-
ence (p<0.05).
DISCUSSION
Our study reveals that a majority of the Medicare benefi-
ciaries with diabetes identified in this analysis were receiving lipid-
lowering and ACEI/ARB therapies. But a substantial percent-
age of patients with diabetes did not receive these therapies.
These results suggest higher ACEI/ARB and lipid-lower-
ing therapy utilization rates in Rhode Island than those reported
nationally and in other locales. For example, using data from the
2003 Medicare Current Beneficiary Survey, Tjia and Briesacher3
reported ACEI/ARB and statin rates of use among seniors with
diabetes to be less than 50%. In another study using data from
the National Ambulatory Medical Care Survey, Segars and Lea2
found that fewer than one in four visits made by diabetic pa-
tients included mention of the prescribing of a statin medica-
tion. In another study of more than 30,000 diabetic Medicare
patients in Pennsylvania, Winkelmayer et al4 reported rates of
use of ACEI/ARB therapy to be approximately 50%.
Table 1.  Patient and Provider Characteristics
among a Sample of Diabetic Medicare Part D
Plan Enrollees in Rhode Island, 2006 and 2007
Characteristics January 1 – January 1 –
June 30, 2006 June 30, 2007
N = 5,009 N = 7,331
n (%) n (%)
Age (years)
   50-64 621 (12.4) 916 (12.5)
   65-74 2,080 (41.5) 3,108 (42.4)
   75 + 2,308 (46.1) 3,307 (45.1)
Gender
   Female 2,989 (59.7) 4,390 (59.9)
   Male 2,020 (40.3) 2,940 (40.1)
Coronary artery
disease
(receiving nitrates)
   Yes 461   (9.2) 635   (8.7)
   No 4,548 (90.8) 6,696 (91.3)
Physician affiliation
   Group practice
   collaborator 2,795 (55.8) 4,083 (55.7)
   Other 2,214 (44.2) 3,248 (44.3)
Endocrinologist care
   Yes 708 (14.1) 1,071 (14.6)
   No 4,301 (85.9) 6,260 (85.4)
Table 2. Use of ACEI/ARB and Lipid-lowering
Medications among a Sample of Diabetic
Medicare Part D Plan Enrollees in Rhode
Island, 2006 and 2007
January 1 – January 1 –
June 30, 2006 June 30, 2007
N = 5,009 N = 7,331
n (%) n (%)
ACEI/ARB 3,478 (69.4) 5,123 (69.9)
Lipid therapy 3,165 (63.2) 4,796 (65.4)
Abbreviation: ACEI/ARB = angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers
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Caution should be applied in comparing our results with
other research, given differing data sources, populations, and
methodologies. Yet it is evident that in our study, ACEI/ARB
and lipid-lowering medications were frequently prescribed
among diabetic Medicare beneficiaries, and at higher rates than
reported elsewhere.
Patients in the 65-74 year old age group received both
medication classes more frequently than those in the younger
and older age categories. Perhaps this indicates a greater preva-
lence of severe illness among the oldest patients, such as ad-
vanced renal disease and other conditions where lipid man-
agement was a lesser priority. Yet the less frequent utilization of
lipid-lowering medications among the oldest patients perhaps
reflects a lack of clinical aggressiveness that may not be justi-
fied.9  The lower frequency of use of these medications among
younger patients is also of concern. Physicians may be less in-
clined to prescribe these medications among younger, healthier
diabetic patients. Perhaps this results from  younger patients’
poorer adherence in refilling medications. Regardless of the
cause, our analyses point out that younger diabetic patients
received these medications less frequently.
To determine if these medications were more likely to be
received among patients having coronary disease, we used a
proxy of receiving nitrate-containing prescriptions to identify
such patients. While this method is a poorly sensitive means for
identifying patients with coronary disease, we believed it to be
sufficiently specific, and would provide some evidence of
known-groups validity. The results revealed that patients re-
ceiving prescriptions for nitrate-containing medications also
more frequently received ACEI/ARB and lipid-lowering medi-
cations. Among users of nitrate-containing products, approxi-
mately 1 in 4 did not receive a dispensing for a lipid-lowering
medication during the study timeframe.
This project entailed collaboration with local physician
group practices. We sought to determine if ACEI/ARB and
lipid-lowering drug utilization rates were higher among physi-
cians affiliated with these practices, compared with overall rates
among physicians not affiliated with these practices. We found
that rates of use of these medications were higher for patients
receiving prescriptions from physicians affiliated with one of
the collaborating group practices
As a final sub-group analysis, we determined if rates of
medication use were higher when a patient was receiving care
from an endocrinologist. Indeed, patients receiving medica-
tions from an endocrinologist more frequently filled prescrip-
tions for ACEI/ARB and lipid-lowering therapies, with a sub-
stantial and statistically significant difference in the use of lipid-
lowering therapies (72% versus 64%, p<0.05). While one may
theorize that patients receiving care from an endocrinologist
may have been further along the continuum of disease, we note
that statin therapy is recommended for most senior patients
with diabetes.10, 11
Several factors may explain why the utilization rates for these
medications are less than 100%. First, the pharmacy claims data
used for this analysis identified dispensed prescriptions only.  It is
likely that many patients were prescribed these medications yet
did not refill them, because patient adherence to chronic medi-
cation therapies is poor.12, 13 For this reason we applied a liberal
threshold in classifying patients as using these therapies, giving
credit even if a patient received just one prescription dispensing
during the 6-month measurement period.
A second explanation for the lower calculated rates of use
of these medications pertains to our inability to identify and
exclude patients having a contraindication to these drug thera-
pies. However, for both lipid-lowing and ACEI/ARB medica-
tions, many types of contraindications to one class of drugs
would not preclude the use of a medication from a different
class. For example, ARB medications would be an acceptable
alternative for most patients that experienced a bothersome
cough from an ACEI. Similarly, because some patients are
poorly tolerant of statin medications, we also included non-
statin lipid-lowering medications such as fibrates and bile acid
resins in our analysis. We do not mean to imply that these other
classes of lipid-lowering medications are acceptable and evi-
dence-based alternatives to statin therapy, but rather may have
been a necessary second-line option.
Third, patients may have received medications as samples,
or bought these medications for cash through discount pro-
grams (e.g. $4 generics). The data provided by the Part D
drug plans would not have captured this data. Yet the pa-
tients in this study were identified as having diabetes based
on their receipt of prescription medication dispensings for
hypoglycemic medications under Part D, indicating that pa-
tients were utilizing their Part D benefit at least to purchase
some drugs.
Table 3.  Use of ACEI/ARB and Lipid-lowering
Medications According to Patient and Provider
Characteristics, January 1 – June 30,  2007
(N = 7,331)
Characteristic ACEI/ARB Lipid therapy
n (%) n (%)
Overall percentage: 5,123 (69.9) 4,796 (65.4)
Age (years)
   50-64 611 (66.7) 591 (64.5)
   65-74 2,280 (73.4) 2,190 (70.5)
   75 + 2,232 (67.5) 2,015 (60.9)
Gender
   Female 3,236 (73.7) 3,090 (70.4)
   Male 2,063 (70.2) 1,840 (62.6)
Coronary artery disease
(receiving nitrates)
   Yes 473 (74.5) 488 (76.9)
   No 4,650 (69.4) 4,308 (64.3)
Physician affiliation
      Group practice
      collaborator 2,930 (71.8) 2,769 (67.8)
      Other 2,193 (67.5) 2,027 (62.4)
Endocrinologist care
   Yes 770 (71.9) 774 (72.3)
   No 4,353 (69.5) 4,022 (64.3)
Abbreviation: ACEI/ARB = angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers
 p < 0.05 for all comparisons except by endocrinologist care among patients
receiving ACEI/ARB therapy
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Fourth, to mitigate the potential effect of being in the Part
D coverage gap (i.e. the “donut hole”), we analyzed pharmacy
claims data from the first 6 months of the year, before most
patients would have fallen into that gap.
CONCLUSION
This report describes rates of use of two clinically impor-
tant drug therapies for patients having diabetes mellitus.  While
a majority of patients were receiving these medications, approxi-
mately 30% of patients did not fill prescriptions for an ACEI/
ARB therapy, while 35% of patients did not receive a dispens-
ing for a lipid-lowering medication. We note that this may re-
flect either failure to prescribe, or the failure of patient persis-
tence in refilling medication. We cannot ascertain which cause
may have contributed the most to our findings.
Patients received these medications more frequently if they
were age 65-74 years (compared with younger and older
groups), and also if they were female. Patients dispensed medi-
cations prescribed by a physician affiliated with one of the col-
laborating provider groups more frequently received these
therapies. Lipid-lowering medications were more frequently
utilized by patients under the care of an endocrinologist.
We hope these findings may help identify patients who
should be receiving these therapies.
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